RECENT LSE market entrant Kanabo Group has inked a major production deal with PharmaCann Polska to supply up to 36,000 cartridges a month for its VapePod medical cannabis device.
Following its successful IPO last month the creation of this customized production line for Kanabo’s VapePod cartridges is another milestone for the company.
The initial production target is around 36,000 cartridges a month with the potential to increase production later in the year, it said in a press release.
Warsaw-based PharmaCann Polska is part of the PHCANN International Group, with fully-licensed indoor cultivation facilities and an EU-GMP standard extraction facility for production cannabinoid products.
Avihu Tamir, CEO Kanabo Group said: “Following the increased fund-raise achieved at the IPO, we are able to accelerate preparations for supply of medicinal cannabis products in addition to building our CBD Wellness business. “
Yuval Soiref, Director of Business Development, PHCANN International: “As part of our expansion strategy, we are happy to sign this milestone agreement with Kanabo to bring innovative cannabis products to the UK, Europe and Israel. I believe this will open a new era of medical delivery methods in the cannabis industry.”
